SEC Comment Letter 0000000000-23-006742 to Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: June 23, 2023 · CIK: 0001601936 · Accession: 0000000000-23-006742
AI Filing Summary & Sentiment
File numbers found in text: 333-272741
Letter
United States securities and exchange commission logo June 23, 2023 Thomas Meyer, Ph.D. President Altamira Therapeutics Ltd. 8 The Green, Suite 300 Dover, DE 19901 Re:Altamira Therapeutics Ltd. Registration Statement on Form F-1 Filed June 16, 2023 File No. 333-272741 Dear Thomas Meyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alex Dinur, Esq.
Show Raw Text
United States securities and exchange commission logo
June 23, 2023
Thomas Meyer, Ph.D.
President
Altamira Therapeutics Ltd.
8 The Green, Suite 300
Dover, DE 19901
Re:Altamira Therapeutics Ltd.
Registration Statement on Form F-1
Filed June 16, 2023
File No. 333-272741
Dear Thomas Meyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alex Dinur, Esq.